<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00438672</url>
  </required_header>
  <id_info>
    <org_study_id>2003-P-000322</org_study_id>
    <nct_id>NCT00438672</nct_id>
  </id_info>
  <brief_title>Corticosteroid Injection for Common Upper Extremity Problems</brief_title>
  <official_title>Corticosteroid Injection for Common Upper Extremity Problems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare the effectiveness of a steroid injection to a placebo
      (inactive substance) in the treatment of lateral elbow pain, deQuervain's tendonitis, or base
      of the thumb carpometacarpal (CMC) arthritis. We are also trying to identify which
      personality factors and mindsets influence perceptions of elbow, wrist and hand pain. We hope
      to enroll 213 subjects in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pain at the origin of the extensor carpi radialis is an extremely common problem. Most
      patients are between 35 and 55 years of age. This problem has been referred to as tennis
      elbow, but fewer than 10% of patients with this problem play tennis, and it is not a common
      problem among professional tennis players. The problem is most commonly called lateral
      epicondylitis in spite of the fact that pathology specimens show no evidence of an
      inflammatory process. Instead, tissue necrosis and other findings suggestive of a
      degenerative process are seen. Previous clinical trials have noted improvement in 80% of
      patients in one year, even in placebo groups, suggesting that this is a self-limited rather
      than a progressive disorder.

      de Quervain's tenosynovitis and carpometacarpal (CMC) arthritis are also very common upper
      extremity problems. In de Quervain's tendonitis, inflammation in the first dorsal compartment
      of the wrist causes tenderness and chronic pain in the radial styloid region when forming a
      fist or using the thumb. CMC arthritis, most common in women 40-70, causes pain at the base
      of the thumb. Descriptions of the severity of this condition can range from stiffness to
      disability, and are associated with complaints of discomfort with pinching and gripping.

      These are frustrating conditions, particularly for active people. As a consequence, varied
      treatments are used routinely in spite of limited scientific support. These treatments can be
      costly, some have risks, and all of them may reinforce the idea that there is a quick fix or
      miracle cure. Physicians and patients alike favor quick, direct treatments, but these are not
      always available. In the absence of effective treatment, the role of the physician is to
      encourage adaptive behaviors based upon an understanding of the nature of the illness.

      Lateral elbow pain, de Quervain's tenosynovitis and CMC arthritis are extremely common and
      not all patients seek a physician's adviceâ€”many develop adaptive behaviors and manage well on
      their own. Our research unit has taken interest in studying psychological factors that may be
      associated with coming to the doctor and poor adaptation to symptoms and dysfunction. These
      are certainly a factor in the treatment of these conditions.

      A condition that is extremely common; is painful and disabling; and has no clear etiology,
      pathophysiology, or cure represents a tempting market for products and devices claiming to
      offer relief. The marketing and application of these devices reinforces patient's desires for
      a quick fix, miracle cure. It also tends to take advantage of people with less adaptive
      health behaviors. Conscientious use of treatments in this setting requires strong evidence of
      their safety and efficacy.

      Injection of corticosteroids is a common treatment for lateral elbow pain, de Quervain's
      tenosynovitis and CMC arthritis. Injections are delivered into the origin of the extensor
      carpi radialis brevis, into the first dorsal compartment of the wrist or into the
      trapeziometacarpal (TMC) joint, respectively. Several studies have tested the efficacy of
      steroid injections, including some prospective randomized trials. However, it is remarkable
      that only one of these have compared corticosteroid injection to placebo injection,
      especially in light of the fact that conditions like lateral elbow pain and de Quervain's
      tenosynovitis may be self-limiting. The psychological factors associated with receiving an
      injection may be important mediators of any treatment effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disabilities of the Arm, Shoulder, and Hand (DASH) Questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>The DASH questionnaire measures arm-specific perceived disability. It contains 30 items and is scaled between zero and 100 with higher scores indicating worse upper-extremity function.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Scale for Pain</measure>
    <time_frame>6 months</time_frame>
    <description>Pain is measured on a 10 cm long line that starts at 0 on the left and ends with 10 on the right. A score of 0 represents no pain at all, and a score of 10 represents the worst pain ever. The individual score is measured using a measuring rod, measuring the distance from the left border in centimeters.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Lateral Elbow Pain</condition>
  <arm_group>
    <arm_group_label>Dequervains</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The de Quervain's injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and DeQuervain's is also fairly uncommon. Therefore, the trial wasn't feasible for this diagnosis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lateral Epicondylitis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CMC Arthritis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The CMC Arthritis injection study was terminated due to difficulty with enrollment. A large percentage of patients declined, and it was decided that the trial wasn't feasible for this diagnosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Injection</intervention_name>
    <description>Injection without steroid</description>
    <arm_group_label>Dequervains</arm_group_label>
    <arm_group_label>Lateral Epicondylitis</arm_group_label>
    <arm_group_label>CMC Arthritis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Steroid (dexamethasone) Injection</intervention_name>
    <description>Injection with steroid (dexamethasone)</description>
    <arm_group_label>Dequervains</arm_group_label>
    <arm_group_label>Lateral Epicondylitis</arm_group_label>
    <arm_group_label>CMC Arthritis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 64 years

          -  onset of pain within the past 6 months

          -  willing to try a steroid injection in the elbow

        Exclusion Criteria:

          -  systemic inflammatory diseases (e.g., rheumatoid arthritis)

          -  pregnancy

          -  prior steroid injection, iontophoresis treatments with corticosteroids, or surgery for
             their pain

          -  history of adverse reaction to lidocaine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Ring, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2007</study_first_submitted>
  <study_first_submitted_qc>February 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2007</study_first_posted>
  <results_first_submitted>March 22, 2012</results_first_submitted>
  <results_first_submitted_qc>April 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 28, 2012</results_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>David C. Ring, MD</investigator_full_name>
    <investigator_title>Director of Research, Hand Service</investigator_title>
  </responsible_party>
  <keyword>lateral elbow pain</keyword>
  <keyword>tennis elbow</keyword>
  <keyword>pain</keyword>
  <keyword>psychology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexamethasone Cohort</title>
          <description>Single injection of 1 mL dexamethasone mixed with 1 mL 1% lidocaine without epinephrine</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Lidocaine Only) Cohort</title>
          <description>Single injection of 2 mL 1% lidocaine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexamethasone Cohort</title>
          <description>Single injection of 1 mL dexamethasone mixed with 1 mL 1% lidocaine without epinephrine</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Lidocaine Only) Cohort</title>
          <description>Single injection of 2 mL 1% lidocaine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="8"/>
                    <measurement group_id="B2" value="49" spread="10"/>
                    <measurement group_id="B3" value="49" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Disabilities of the Arm, Shoulder, and Hand (DASH) Questionnaire</title>
        <description>The DASH questionnaire measures arm-specific perceived disability. It contains 30 items and is scaled between zero and 100 with higher scores indicating worse upper-extremity function.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone Cohort</title>
            <description>Single injection of 1 mL dexamethasone mixed with 1 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Lidocaine Only) Cohort</title>
            <description>Single injection of 2 mL 1% lidocaine</description>
          </group>
        </group_list>
        <measure>
          <title>Disabilities of the Arm, Shoulder, and Hand (DASH) Questionnaire</title>
          <description>The DASH questionnaire measures arm-specific perceived disability. It contains 30 items and is scaled between zero and 100 with higher scores indicating worse upper-extremity function.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18" spread="20"/>
                    <measurement group_id="O2" value="13" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Scale for Pain</title>
        <description>Pain is measured on a 10 cm long line that starts at 0 on the left and ends with 10 on the right. A score of 0 represents no pain at all, and a score of 10 represents the worst pain ever. The individual score is measured using a measuring rod, measuring the distance from the left border in centimeters.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexamethasone Cohort</title>
            <description>Single injection of 1 mL dexamethasone mixed with 1 mL 1% lidocaine without epinephrine</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Lidocaine Only) Cohort</title>
            <description>Single injection of 2 mL 1% lidocaine</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Scale for Pain</title>
          <description>Pain is measured on a 10 cm long line that starts at 0 on the left and ends with 10 on the right. A score of 0 represents no pain at all, and a score of 10 represents the worst pain ever. The individual score is measured using a measuring rod, measuring the distance from the left border in centimeters.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" spread="2.9"/>
                    <measurement group_id="O2" value="1.7" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexamethasone Cohort</title>
          <description>Single injection of 1 mL dexamethasone mixed with 1 mL 1% lidocaine without epinephrine</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Lidocaine Only) Cohort</title>
          <description>Single injection of 2 mL 1% lidocaine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Ring</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-3953</phone>
      <email>dring@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

